米氮平联合西酞普兰治疗抑郁症患者睡眠障碍的临床观察

发布时间：2018-04-19 23:32

本文选题：西酞普兰 + 米氮平　；参考：《中国药房》2017年05期

【摘要】：目的:探讨西酞普兰联合米氮平治疗抑郁症患者睡眠障碍临床疗效和安全性。方法:选取抑郁症伴睡眠障碍患者165例,按随机数字表法分为对照组(82例)和治疗组(83例)。对照组患者给予草酸艾司西酞普兰片10 mg,每晚1次,根据患者病情,每日剂量可增至20 mg;治疗组患者在对照组的基础上加用米氮平片15 mg,每晚1次,1周后剂量增至30 mg。两组患者均持续治疗6个月。观察两组患者治疗前后汉密尔顿抑郁量表17项(HAMD-17)、蒙哥马利抑郁评定量表(MADRS)评分,采用匹兹堡睡眠质量指数量表(PSQI)评估两组患者治疗前后的睡眠质量,采用多导睡眠仪测定患者治疗前后睡眠结构,比较两组患者临床疗效及不良反应发生情况。结果:治疗前,两组患者HAMD-17、MADRS、PSQI评分及睡眠结构指标比较,差异均无统计学意义(P0.05);治疗后,两组患者上述评分及指标均显著改善,且治疗组显著优于对照组,差异均有统计学意义(P0.05)。治疗组患者临床总有效率为97.47%,显著高于对照组的78.95%,差异有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:米氮平联合西酞普兰治疗抑郁症患者睡眠障碍疗效显著,可明显改善抑郁症患者睡眠结构、调整睡眠周期、提高睡眠质量,且安全性较好。
[Abstract]:Objective: to investigate the clinical efficacy and safety of citalopram combined with mirtazapine in the treatment of sleep disorders in patients with depression. Methods: 165 depressive patients with sleep disorder were randomly divided into two groups: control group (n = 82) and treatment group (n = 83). The patients in the control group were given 10 mg of oxalcitalopram, once a night, according to the patient's condition, the daily dose could be increased to 20 mg, and the treatment group was treated with 15 mg of metozapine on the basis of the control group, and the dosage increased to 30 mg once a week every night. The patients in both groups were treated continuously for 6 months. Before and after treatment, 17 items of Hamilton Depression scale (Hamilton Depression scale) and 17 items of Montgomery Depression rating scale (Montgomery Depression rating scale) were assessed. Pittsburgh Sleep quality Index (PSQI) was used to evaluate the sleep quality before and after treatment. The sleep structure of patients before and after treatment was measured by polysomnography, and the clinical efficacy and adverse reactions were compared between the two groups. Results: before treatment, there was no significant difference between the two groups in the scores of HAMD-17 MADRSSI PSQI and sleep structure, but after treatment, the above scores and indexes of the two groups were significantly improved, and the treatment group was significantly better than the control group, and the difference was statistically significant (P 0.05). The total clinical effective rate of the treatment group was 97.47, which was significantly higher than that of the control group (78.95), the difference being statistically significant (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: Mitzapine combined with citalopram is effective in the treatment of sleep disorders in patients with depression. It can improve sleep structure, adjust sleep cycle and improve sleep quality in patients with depression.
【作者单位】：玉溪市人民医院神内一科;
【分类号】：R749.4

【参考文献】